Tesla shares rise on strong 2nd-quarter profits, but the company still needs cash. Bill Mann analyzes Tesla’s short-term future and why Elon Musk continues to set ambitious production targets. Teva Pharmaceuticals sinks to a 13-year low on a bad 2nd-quarter report combined with slashing the dividend. Plus, Bill shares observations, both business and personal, from his recent trip to Africa.
Thanks to Bombfell for supporting The Motley Fool. Get $25 off your first purchase at http://bombfell.com/fool
